Optimization of expression of untagged and histidine-tagged human recombinant thrombin precursors in Escherichia coli

[1]  Bettina Bardl,et al.  Trace element associated reduction of norleucine and norvaline accumulation during oxygen limitation in a recombinant Escherichia coli fermentation , 2013, Microbial Cell Factories.

[2]  K. Bayer,et al.  A Comparative Analysis of Industrial Escherichia coli K–12 and B Strains in High-Glucose Batch Cultivations on Process-, Transcriptome- and Proteome Level , 2013, PloS one.

[3]  Rachel Chen.  Bacterial expression systems for recombinant protein production: E. coli and beyond. , 2012, Biotechnology advances.

[4]  O. Valerius,et al.  Codon optimization for high level expression of human bone morphogenetic protein-2 in Escherichia coli. , 2012, Protein expression and purification.

[5]  Sang Yup Lee,et al.  Comparative multi-omics systems analysis of Escherichia coli strains B and K-12 , 2012, Genome Biology.

[6]  Shaozhou Zhu,et al.  A simple and effective strategy for solving the problem of inclusion bodies in recombinant protein technology: His-tag deletions enhance soluble expression , 2012, Applied Microbiology and Biotechnology.

[7]  A. Tiwari,et al.  Enhanced periplasmic expression of high affinity humanized scFv against Hepatitis B surface antigen by codon optimization. , 2010, Protein expression and purification.

[8]  Wesley K. Lew,et al.  Thrombin use in surgery: an evidence-based review of its clinical use , 2010, Journal of blood medicine.

[9]  J. Jilková,et al.  High level expression and purification of antimicrobial human cathelicidin LL-37 in Escherichia coli , 2010, Applied Microbiology and Biotechnology.

[10]  Haeyoung Jeong,et al.  Genomics, Biological Features, and Biotechnological Applications of Escherichia coli B: “Is B for better?!” , 2009 .

[11]  Peter Neubauer,et al.  High cell density media for Escherichia coli are generally designed for aerobic cultivations – consequences for large-scale bioprocesses and shake flask cultures , 2008, Microbial cell factories.

[12]  Sudhir Sahdev,et al.  Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies , 2007, Molecular and Cellular Biochemistry.

[13]  Erika Giste,et al.  Preclinical safety of recombinant human thrombin. , 2007, Regulatory toxicology and pharmacology : RTP.

[14]  J. Reseland,et al.  Histidine tag fusion increases expression levels of active recombinant amelogenin in Escherichia coli. , 2006, Protein expression and purification.

[15]  K. Lewis,et al.  Comparison of recombinant human thrombin and plasma-derived human α-thrombin , 2006 .

[16]  K. Lewis,et al.  Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. , 2006, Seminars in thrombosis and hemostasis.

[17]  F. Studier,et al.  Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.

[18]  S. Singh,et al.  Solubilization and refolding of bacterial inclusion body proteins. , 2005, Journal of bioscience and bioengineering.

[19]  S. Govindarajan,et al.  Codon bias and heterologous protein expression. , 2004, Trends in biotechnology.

[20]  H. Nakatake,et al.  Preparation of recombinant alpha-thrombin: high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin. , 2004, Journal of biochemistry.

[21]  K. Berndt,et al.  Codon optimization reveals critical factors for high level expression of two rare codon genes in Escherichia coli: RNA stability and secondary structure but not tRNA abundance. , 2004, Biochemical and biophysical research communications.

[22]  Martin Hammarström,et al.  His tag effect on solubility of human proteins produced in Escherichia coli: a comparison between four expression vectors , 2004, Journal of Structural and Functional Genomics.

[23]  S. Tarlo,et al.  Anaphylaxis from topical bovine thrombin (Thrombostat®) during haemodialysis and evaluation of sensitization among a dialysis population , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  Peter Neubauer,et al.  Cheese whey-induced high-cell-density production of recombinant proteins in Escherichia coli , 2003, Microbial cell factories.

[25]  Sung-Hou Kim,et al.  Expression of soluble recombinant proteins in a cell-free system using a 96-well format. , 2003, Journal of biochemical and biophysical methods.

[26]  H. Nakatake,et al.  An efficient refolding method for the preparation of recombinant human prethrombin-2 and characterization of the recombinant-derived alpha-thrombin. , 2001, Journal of biochemistry.

[27]  T Gojobori,et al.  Codon and base biases after the initiation codon of the open reading frames in the Escherichia coli genome and their influence on the translation efficiency. , 2001, Journal of biochemistry.

[28]  F. Baneyx.  Recombinant protein expression in Escherichia coli. , 1999, Current opinion in biotechnology.

[29]  R. Greasham,et al.  Chemically defined media for commercial fermentations , 1999, Applied Microbiology and Biotechnology.

[30]  R. Hale,et al.  Codon optimization of the gene encoding a domain from human type 1 neurofibromin protein results in a threefold improvement in expression level in Escherichia coli. , 1998, Protein expression and purification.

[31]  H. Hemker,et al.  Autocatalytic peptide bond cleavages in prothrombin and meizothrombin. , 1998, Biochemistry.

[32]  E. Schlaeger,et al.  Stable expression and purification of a secreted human recombinant prethrombin-2 and its activation to thrombin. , 1997, Protein expression and purification.

[33]  J. Shiloach,et al.  Effect of glucose supply strategy on acetate accumulation, growth, and recombinant protein production by Escherichia coli BL21 (λDE3) and Escherichia coli JM109 , 2000, Biotechnology and bioengineering.

[34]  F. Baneyx,et al.  Recombinant protein expression at low temperatures under the transcriptional control of the major Escherichia coli cold shock promoter cspA , 1996, Applied and environmental microbiology.

[35]  H. Scheraga,et al.  Expression and Folding of Recombinant Bovine Prethrombin-2 and Its Activation to Thrombin (*) , 1995, The Journal of Biological Chemistry.

[36]  M. Mandrand,et al.  Antagonistic effect of nickel on the fermentative growth of Escherichia coli K-12 and comparison of nickel and cobalt toxicity on the aerobic and anaerobic growth. , 1994, Environmental health perspectives.

[37]  D. Banfield,et al.  Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A, and R284A). , 1994, The Journal of biological chemistry.

[38]  T. Ortel,et al.  Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis , 1994, American journal of hematology.

[39]  C. Esmon,et al.  Interaction of thrombin des-ETW with antithrombin III, the Kunitz inhibitors, thrombomodulin and protein C. Structural link between the autolysis loop and the Tyr-Pro-Pro-Trp insertion of thrombin. , 1992, The Journal of biological chemistry.

[40]  K. Hahm,et al.  Purification and activation of recombinant human Prethrombin 2 produced in E. coli , 1992 .